53 related articles for article (PubMed ID: 12694391)
21. A translational approach to vocalization deficits and neural recovery after behavioral treatment in Parkinson disease.
Ciucci MR; Vinney L; Wahoske EJ; Connor NP
J Commun Disord; 2010; 43(4):319-26. PubMed ID: 20434728
[TBL] [Abstract][Full Text] [Related]
22. Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
Natale G; Colella M; De Carluccio M; Lelli D; Paffi A; Carducci F; Apollonio F; Palacios D; Viscomi MT; Liberti M; Ghiglieri V
Mov Disord; 2023 Dec; 38(12):2173-2184. PubMed ID: 37700489
[TBL] [Abstract][Full Text] [Related]
23. Focused ultrasound on the substantia nigra enables safe neurotensin-polyplex nanoparticle-mediated gene delivery to dopaminergic neurons intranasally and by blood circulation.
Mascotte-Cruz JU; Vera A; Leija L; Lopez-Salas FE; Gradzielski M; Koetz J; Gatica-García B; Rodríguez-Oviedo CP; Valenzuela-Arzeta IE; Escobedo L; Reyes-Corona D; Gutierrez-Castillo ME; Maldonado-Berny M; Espadas-Alvarez AJ; Orozco-Barrios CE; Martinez-Fong D
Discov Nano; 2024 Apr; 19(1):60. PubMed ID: 38564106
[TBL] [Abstract][Full Text] [Related]
24. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model.
Lee HJ; Park J; Yoon OJ; Kim HW; Lee DY; Kim DH; Lee WB; Lee NE; Bonventre JV; Kim SS
Nat Nanotechnol; 2011 Feb; 6(2):121-125. PubMed ID: 21278749
[TBL] [Abstract][Full Text] [Related]
25. Retraction Note: Dopaminergic Neuronal Death in Substantia Nigra Associates with Serum Levels of Total Bilirubin, Selenium, and Zinc: Evidences from 6-Hydroxydopamine Animal Model of Parkinson's Disease.
Sophiabadi M; Rastgoo N; Haghdoost-Yazdi H
Biol Trace Elem Res; 2024 May; ():. PubMed ID: 38809398
[No Abstract] [Full Text] [Related]
26. Cytokine-, Neurotrophin-, and Motor Rehabilitation-Induced Plasticity in Parkinson's Disease.
Policastro G; Brunelli M; Tinazzi M; Chiamulera C; Emerich DF; Paolone G
Neural Plast; 2020; 2020():8814028. PubMed ID: 33293946
[TBL] [Abstract][Full Text] [Related]
27. Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson's Disease.
Xicoy H; Brouwers JF; Wieringa B; Martens GJM
Cells; 2020 Aug; 9(9):. PubMed ID: 32858884
[TBL] [Abstract][Full Text] [Related]
28. Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes.
Neal M; Luo J; Harischandra DS; Gordon R; Sarkar S; Jin H; Anantharam V; Désaubry L; Kanthasamy A; Kanthasamy A
Glia; 2018 Oct; 66(10):2137-2157. PubMed ID: 30277602
[TBL] [Abstract][Full Text] [Related]
29. New Progress on the Role of Glia in Iron Metabolism and Iron-Induced Degeneration of Dopamine Neurons in Parkinson's Disease.
Xu H; Wang Y; Song N; Wang J; Jiang H; Xie J
Front Mol Neurosci; 2017; 10():455. PubMed ID: 29403352
[TBL] [Abstract][Full Text] [Related]
30. Evidence for cross-hemispheric preconditioning in experimental Parkinson's disease.
Weilnau JN; Carcella MA; Miner KM; Bhatia TN; Hutchison DF; Pant DB; Nouraei N; Leak RK
Brain Struct Funct; 2018 Apr; 223(3):1255-1273. PubMed ID: 29103154
[TBL] [Abstract][Full Text] [Related]
31. Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice.
Vingill S; Brockelt D; Lancelin C; Tatenhorst L; Dontcheva G; Preisinger C; Schwedhelm-Domeyer N; Joseph S; Mitkovski M; Goebbels S; Nave KA; Schulz JB; Marquardt T; Lingor P; Stegmüller J
EMBO J; 2016 Sep; 35(18):2008-25. PubMed ID: 27497298
[TBL] [Abstract][Full Text] [Related]
32. Secreted miR-34a in astrocytic shedding vesicles enhanced the vulnerability of dopaminergic neurons to neurotoxins by targeting Bcl-2.
Mao S; Sun Q; Xiao H; Zhang C; Li L
Protein Cell; 2015 Jul; 6(7):529-540. PubMed ID: 26091620
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?
Leal MC; Casabona JC; Puntel M; Pitossi FJ
Front Cell Neurosci; 2013; 7():53. PubMed ID: 23641196
[TBL] [Abstract][Full Text] [Related]
34. Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1.
Shimshek DR; Schweizer T; Schmid P; van der Putten PH
Sci Rep; 2012; 2():262. PubMed ID: 22355774
[TBL] [Abstract][Full Text] [Related]
35. The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation.
Roca V; Casabona JC; Radice P; Murta V; Pitossi FJ
Parkinsons Dis; 2011; 2011():931572. PubMed ID: 21687774
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease.
Litteljohn D; Mangano E; Clarke M; Bobyn J; Moloney K; Hayley S
Parkinsons Dis; 2010 Dec; 2011():713517. PubMed ID: 21234362
[TBL] [Abstract][Full Text] [Related]
37. Effect of intranigral injection of GDNF and EGF on the survival and possible differentiation fate of progenitors and immature neurons in 6-OHDA-lesioned rats.
Yu ZQ; Zha JH; Liu HM; Ding YX; Wang YQ; Wang HJ; Gao DS
Neurochem Res; 2009 Dec; 34(12):2089-101. PubMed ID: 19472051
[TBL] [Abstract][Full Text] [Related]
38. The role of alpha-synuclein in brain lipid metabolism: a downstream impact on brain inflammatory response.
Golovko MY; Barceló-Coblijn G; Castagnet PI; Austin S; Combs CK; Murphy EJ
Mol Cell Biochem; 2009 Jun; 326(1-2):55-66. PubMed ID: 19116775
[TBL] [Abstract][Full Text] [Related]
39. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.
Johnston LC; Su X; Maguire-Zeiss K; Horovitz K; Ankoudinova I; Guschin D; Hadaczek P; Federoff HJ; Bankiewicz K; Forsayeth J
Mol Ther; 2008 Aug; 16(8):1392-9. PubMed ID: 18545225
[TBL] [Abstract][Full Text] [Related]
40. Toxin-induced models of Parkinson's disease.
Bové J; Prou D; Perier C; Przedborski S
NeuroRx; 2005 Jul; 2(3):484-94. PubMed ID: 16389312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
